Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company

Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip

Fineline Cube Jul 21, 2023

US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second...

Company Drug

Jiangsu Simcere Pharmaceutical Gets NMPA Approval for Quviviq, Anti-Insomnia Drug

Fineline Cube Jul 21, 2023

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced the receipt of clinical trial approval...

Company Deals

Livzon Pharmaceutical Secures Licensing Agreement for Synergy Pharma’s HHT120 in Greater China

Fineline Cube Jul 21, 2023

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with fellow Chinese...

Company Deals Digital

Alibaba Health and Daiichi Sankyo Partner to Innovate in Digital Healthcare Services

Fineline Cube Jul 20, 2023

China’s Alibaba Health Information Technology Ltd (HKG: 0241) has entered into a strategic partnership with...

Drug

Pfizer’s GBS Vaccine Candidate GBS6 Shows Promise in Phase II Maternal Immunization Study

Fineline Cube Jul 20, 2023

Pfizer (NYSE: PFE) has this week published the Phase II data for its Group B...

Legal / IP Policy / Regulatory

US Merger Guidelines Updated: Public Comment Sought on Antitrust Law Changes

Fineline Cube Jul 20, 2023

The United States has published an update to its merger and acquisition guidelines, seeking public...

Company Drug

Merck and Telix Pharmaceuticals Initiate Phase I Study for CAIX-Expressing Tumors Therapy

Fineline Cube Jul 20, 2023

A Phase I study assessing the combination of German-major Merck’s (NYSE: MRK) DNA-PK inhibitor, peposertib,...

Company Drug

Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB

Fineline Cube Jul 20, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced that the National...

Company Drug

Chongqing Zhifei Biological Launches Phase I Clinical Trial for Group B Meningococcal Vaccine

Fineline Cube Jul 20, 2023

Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the commencement of a Phase I...

Company Drug

Chipscreen Pharmaceutical’s Epidaza Granted Priority Status for DLBCL Treatment in China

Fineline Cube Jul 20, 2023

The Center for Drug Evaluation (CDE) website has announced that Shenzhen Chipscreen Biosciences Co., Ltd’s...

Company Drug

HutchMed’s Elunate-Tyvyt Combo Receives Breakthrough Therapy Designation in China for Endometrial Cancer

Fineline Cube Jul 20, 2023

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the combination of Elunate (fruquintinib)...

Company Drug

Kintor Pharmaceutical Initiates Long-Term Safety Trial for Androgenetic Alopecia Treatment KX-826

Fineline Cube Jul 20, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the start of the long-term safety trial...

Company Deals

Hybribio Ltd and United Imaging Healthcare Form Strategic Partnership to Advance Medical Technology

Fineline Cube Jul 20, 2023

Guangdong-based Hybribio Ltd (SHE: 300639), a leading provider of nucleic acid molecular diagnostic products, has...

Company Deals

Novomics Partners with TopGene to Expand Genomic Testing Services in China

Fineline Cube Jul 20, 2023

South Korea-based molecular diagnostics firm Novomics Co. has announced a strategic partnership with China-based Hubei...

Company

Stemirna Therapeutics Halts mRNA Vaccine Factory Construction Amid Low Demand

Fineline Cube Jul 20, 2023

China-based Stemirna Therapeutics Co., Ltd has decided to halt the construction of a factory intended...

Company Deals

BGI Genomics Partners with Thai Entities to Combat Thalassemia through Genomics and Cell Therapy

Fineline Cube Jul 20, 2023

China-based genomics leader BGI Genomics Co., Ltd (SHE: 300676) has entered into a memorandum of...

Company Drug

Shanghai Junshi Biosciences’ Tuoyi Receives NMPA Review for ES-SCLC Treatment

Fineline Cube Jul 20, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the National Medical...

Company Legal / IP

Sichuan Gowell Pharmaceutical Wins Reversal in Forxiga Patent Infringement Case

Fineline Cube Jul 20, 2023

Sichuan Gowell Pharmaceutical Co., Ltd. has secured a favorable final judgment in its appeal against...

Company Deals

Boyu Capital Acquires Hong Kong Medical Device Company Quasar for Over $600 Million

Fineline Cube Jul 19, 2023

Boyu Capital, according to a Bloomberg report, is set to acquire Quasar, a Hong Kong-based...

Company

Novartis Q2 2023 Results Exceed Expectations with 9% YOY Sales Growth

Fineline Cube Jul 19, 2023

Swiss pharmaceutical major Novartis AG (NYSE: NVS) has reported its financial results for the second...

Posts pagination

1 … 553 554 555 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.